Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Viral load news


From To
Here’s why you test positive for HIV if you’re undetectable

Why might people living with HIV get tested for HIV? Now that we know undetectable equals untransmittable (U=U), some people may have the misconception that if you’re undetectable, you will no longer test positive for HIV. They may think that if they test HIV-negative on an HIV test, they’ll be able to show this to their sex partners as a way to “prove” that they’re undetectable and untransmittable. Or, they may think it will be easier to tell partners they’re HIV-negative rather than undetectable and uninfectious.

11 June 2019
San Francisco AIDS Foundation
Significant health gains from faster switching to second-line ART in sub-Saharan Africa

Switching to second-line antiretroviral therapy (ART) after a single viral load measurement above 1000 copies/ml has the potential to save lives, avert a significant burden of AIDS-related illnesses

29 May 2019
Michael Carter
Abbott gets WHO prequalification for point-of-care HIV test

The World Health Organization has granted prequalification to Abbot's point-of-care test of HIV viral load. WHO's action confirms the diagnostic, m-PIMA HIV-1/2 VL, meets its quality, safety and efficacy standards, potentially giving ministries of health and other funders the confidence to buy the test. Abbott said the diagnostic can expand access to viral load testing in resource-limited settings and, by extension, improve management of HIV.

12 May 2019
Med Tech Drive
Q&A: Understanding persistent low-level viremia in people with HIV

Persistent low-level viremia among people living with HIV who are adhering to treatment is a challenging issue for clinicians, and there is not much guidance available.

19 March 2019
More than 1 year to HIV control raises failure risk almost 10-fold

Failure to reach an undetectable viral load in the first year of antiretroviral therapy (ART) led to nearly a 10-fold higher risk of subsequent virologic failure in a 17,000-person North American analysis [1]. Taking more than 1 year to control HIV did not confer a higher risk of low-level viremia or viral blips in this 6-year study.

15 March 2019
Detectable HIV Despite Treatment? Clonal Expansion Could Be The Culprit

In a study of people with a low but detectable viral load despite adherence to treatment, infected cells were apparently cloning themselves.

14 March 2019
When Undetectable Is Unachievable: Study Offers Insights into HIV Persistence

Rarely, people living with HIV are unable to maintain an undetectable viral load despite strict adherence to daily ART. New NIAID-funded research suggests that this sometimes can occur when a single cell from the HIV reservoir—the population of long-lived HIV-infected cells that ART cannot eradicate—multiplies to create many identical cells that produce enough virus to be detected by standard viral load tests.

11 March 2019
National Institute of Allergy and Infectious Diseases
Are CD4 counts still useful in the 'treat all' era?

CD4 cell testing before starting treatment is still essential even in the era of 'treat all' guidelines, two studies from southern Africa presented at the Conference on

08 March 2019
Keith Alcorn
Point-of-care viral load testing improves treatment outcomes and retention in care

Same-day provision of results from a point-of-care viral load test – rather than waiting weeks for laboratory results to be collected – resulted in a 14% improvement

05 March 2019
Roger Pebody
Viral load monitoring motivates HIV treatment adherence in eSwatini

The treat-all policy will only succeed if people keep taking their HIV treatment. It is important to motivate people who started treatment while they were still feeling well. 

24 February 2019
← First12345...19Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.